Phospholipids form the primary surface-active layer at the alveolar air–liquid interface, while associated proteins contribute to the behavior of that layer. Together, these components reduce interfacial tension during breathing. Their coordinated action helps preserve alveolar stability, allowing the lungs to remain functional rather than repeatedly collapsing and reopening with each respiratory cycle.
Lower surface tension makes the alveoli easier to expand, which improves lung compliance, meaning the lungs can inflate with less mechanical difficulty. More stable alveoli also support the air–liquid interface needed for effective gas exchange. Consequently, an adequate surfactant layer connects physical stabilization of the alveoli with improved respiratory performance.
Treatment depends not only on placing surfactant in the airway but also on its ability to spread across relevant alveolar surfaces. Distribution determines how broadly the surface-active material can reduce interfacial tension and support alveolar stability. For this reason, surfactant composition and delivery are important considerations when developing safer and more effective pulmonary therapies.
In the clinical setting described, exogenous surfactant is administered into the trachea so it can reach the lungs and spread across alveolar surfaces. The procedure therefore links airway delivery with action at the alveolar air–liquid interface. Attention to both administration and subsequent distribution supports the intended improvements in lung compliance and gas exchange.
Premature infants with respiratory distress syndrome are the primary clinical group identified for this treatment. In these patients, pulmonary surfactant therapy is used to address impaired respiratory function by supplying exogenous surface-active material to the lungs. Its clinical relevance comes from the potential to improve lung compliance and gas exchange during a vulnerable period of development.
The principal outcomes are improved lung compliance and gas exchange, because these reflect whether the administered material is supporting alveolar function. Researchers also consider surfactant composition, delivery, and distribution when assessing treatment performance. These factors help guide safer respiratory care and inform development of surfactant-based approaches for acute and chronic lung disease.